ALERT: This system is being upgraded on Tuesday December 12. It will not be available
for use for several hours that day while the upgrade is in progress. Deposits to DukeSpace
will be disabled on Monday December 11, so no new items are to be added to the repository
while the upgrade is in progress. Everything should be back to normal by the end of
day, December 12.
Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.
dc.contributor.author | Hitzler, Johann K | |
dc.contributor.author | He, Wensheng | |
dc.contributor.author | Doyle, John | |
dc.contributor.author | Cairo, Mitchell | |
dc.contributor.author | Camitta, Bruce M | |
dc.contributor.author | Chan, Ka Wah | |
dc.contributor.author | Diaz Perez, Miguel A | |
dc.contributor.author | Fraser, Christopher | |
dc.contributor.author | Gross, Thomas G | |
dc.contributor.author | Horan, John T | |
dc.contributor.author | Kennedy-Nasser, Alana A | |
dc.contributor.author | Kitko, Carrie | |
dc.contributor.author | Kurtzberg, Joanne | |
dc.contributor.author | Lehmann, Leslie | |
dc.contributor.author | O'Brien, Tracey | |
dc.contributor.author | Pulsipher, Michael A | |
dc.contributor.author | Smith, Franklin O | |
dc.contributor.author | Zhang, Mei-Jie | |
dc.contributor.author | Eapen, Mary | |
dc.contributor.author | Carpenter, Paul A | |
dc.contributor.author | CIBMTR Pediatric Cancer Working Committee | |
dc.date.accessioned | 2022-03-23T19:29:52Z | |
dc.date.available | 2022-03-23T19:29:52Z | |
dc.date.issued | 2014-06 | |
dc.identifier.issn | 1545-5009 | |
dc.identifier.issn | 1545-5017 | |
dc.identifier.uri | https://hdl.handle.net/10161/24654 | |
dc.description.abstract | We report on 27 patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) who received allogeneic hematopoietic cell transplantation (HCT) between 2000 and 2009. Seventy-eight percent of patients received myeloablative conditioning and 52% underwent transplantation in second remission. Disease-free survival (DFS) was 24% at a median of 3 years. Post-transplant leukemic relapse was more frequent than expected for children with DS-ALL (54%) than for non-DS ALL. These data suggest leukemic relapse rather than transplant toxicity is the most important cause of treatment failure. Advancements in leukemia control are especially needed for improvement in HCT outcomes for DS-ALL. | |
dc.language | eng | |
dc.publisher | Wiley | |
dc.relation.ispartof | Pediatric blood & cancer | |
dc.relation.isversionof | 10.1002/pbc.24918 | |
dc.subject | CIBMTR Pediatric Cancer Working Committee | |
dc.subject | Humans | |
dc.subject | Down Syndrome | |
dc.subject | Graft vs Host Disease | |
dc.subject | Genetic Predisposition to Disease | |
dc.subject | Recurrence | |
dc.subject | Tacrolimus | |
dc.subject | Cyclosporine | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Immunosuppressive Agents | |
dc.subject | Myeloablative Agonists | |
dc.subject | Disease-Free Survival | |
dc.subject | Treatment Outcome | |
dc.subject | Transplantation Conditioning | |
dc.subject | Combined Modality Therapy | |
dc.subject | Salvage Therapy | |
dc.subject | Whole-Body Irradiation | |
dc.subject | Remission Induction | |
dc.subject | Bone Marrow Transplantation | |
dc.subject | Hematopoietic Stem Cell Transplantation | |
dc.subject | Registries | |
dc.subject | Retrospective Studies | |
dc.subject | Adolescent | |
dc.subject | Adult | |
dc.subject | Child | |
dc.subject | Child, Preschool | |
dc.subject | Infant | |
dc.subject | Living Donors | |
dc.subject | Precursor Cell Lymphoblastic Leukemia-Lymphoma | |
dc.subject | Kaplan-Meier Estimate | |
dc.subject | Allografts | |
dc.title | Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. | |
dc.type | Journal article | |
duke.contributor.id | Kurtzberg, Joanne|0097203 | |
dc.date.updated | 2022-03-23T19:29:52Z | |
pubs.begin-page | 1126 | |
pubs.end-page | 1128 | |
pubs.issue | 6 | |
pubs.organisational-group | Duke | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Pathology | |
pubs.organisational-group | Pediatrics | |
pubs.organisational-group | Duke Cancer Institute | |
pubs.organisational-group | Institutes and Provost's Academic Units | |
pubs.organisational-group | Initiatives | |
pubs.organisational-group | Duke Innovation & Entrepreneurship | |
pubs.organisational-group | Pediatrics, Transplant and Cellular Therapy | |
pubs.publication-status | Published | |
pubs.volume | 61 | |
duke.contributor.orcid | Kurtzberg, Joanne|0000-0002-3370-0703 |
Files in this item
This item appears in the following Collection(s)
- Scholarly Articles
Articles